Japan’s largest drugmaker Takeda Pharmaceutical (TYO: 4502) has sold seven off-patent products in Japan to Teva Takeda Yakuhin.
Takeda says the purpose of the transaction is to offload non-core products and free up cash to reinvest in its core therapeutic areas.
Teva Takeda Yakuhin is a joint venture formed one year ago between Takeda and Israeli generics specialist Teva Pharmaceutical (NYSE: TEVA), with the aim of providing off-patent drugs to the Japanese market.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze